Farletuzumab ecteribulin | Interleukin Related interleukin-related.com

Product Name :
Farletuzumab ecteribulin

Search keywords :
Farletuzumab

drugId :
null

Target Vo:
Folate receptor alpha

Target Vo Short Name :
FOLR1

Moa_Name:
Tubulin polymerisation inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Eisai Co Ltd

Active Company_Name :
Bristol-Myers Squibb Company

Active Indication_Name:
Ovarian Neoplasms

In Active Indication_Name:
Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Phase 2 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
FGFR2/CD332 Antibody
STING Antibody
Phospho-AMPK alpha 1 (Ser496) Antibody: Phospho-AMPK alpha 1 (Ser496) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 64 kDa, targeting to Phospho-AMPK alpha 1 (Ser496). It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts